COSMO PHARMACEUTICALS NV (C43.DE) Stock Price, Forecast & Analysis
Europe - FRA:C43 - NL0011832936 - Common Stock
C43.DE Key Statistics, Chart & Performance
The current stock price of C43.DE is 48.8 EUR. In the past month the price decreased by -17.98%. In the past year, price decreased by -32.22%.
C43.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SAN.PA | SANOFI | 11.82 | 218.78B | ||
| SNW.DE | SANOFI | 11.89 | 220.16B | ||
| MRK.DE | MERCK KGAA | 13.86 | 51.27B | ||
| UCB.BR | UCB SA | 33.97 | 42.42B | ||
| 1BAYN.MI | BAYER AG-REG | 5.81 | 28.59B | ||
| BAYN.DE | BAYER AG-REG | 5.86 | 28.35B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 26.56 | 10.94B | ||
| IPN.PA | IPSEN | 12.69 | 10.92B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 94.33 | 8.73B | ||
| VIRP.PA | VIRBAC SA | 20.63 | 3.00B | ||
| DMP.DE | DERMAPHARM HOLDING SE | 16.88 | 1.81B | ||
| MEDCL.PA | MEDINCELL SA | N/A | 1.01B |
Related stock screener links
About C43.DE
Company Profile
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. The company is headquartered in Dublin, Dublin and currently employs 322 full-time employees. The company went IPO on 2016-05-18. The firm is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Breezula (clascoterone), GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, CB-01-33 (colesevelam), and CB-01-35. The firm's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travelers’ diarrhea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Company Info
COSMO PHARMACEUTICALS NV
Riverside II, Sir John Rogerson's Quay
DUBLIN DUBLIN IE
Employees: 322
Phone: 35318170370
COSMO PHARMACEUTICALS NV / C43.DE FAQ
What does COSMO PHARMACEUTICALS NV do?
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. The company is headquartered in Dublin, Dublin and currently employs 322 full-time employees. The company went IPO on 2016-05-18. The firm is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Breezula (clascoterone), GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, CB-01-33 (colesevelam), and CB-01-35. The firm's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travelers’ diarrhea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
What is the stock price of COSMO PHARMACEUTICALS NV today?
The current stock price of C43.DE is 48.8 EUR. The price decreased by -2.4% in the last trading session.
Does COSMO PHARMACEUTICALS NV pay dividends?
COSMO PHARMACEUTICALS NV (C43.DE) has a dividend yield of 3.85%. The yearly dividend amount is currently 2.
What is the ChartMill technical and fundamental rating of C43 stock?
C43.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 9 out of 10.
Can you provide the PE ratio for C43 stock?
The PE ratio for COSMO PHARMACEUTICALS NV (C43.DE) is 5.98. This is based on the reported non-GAAP earnings per share of 8.16 and the current share price of 48.8 EUR.
What is the expected growth for C43 stock?
The Revenue of COSMO PHARMACEUTICALS NV (C43.DE) is expected to decline by -19.4% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of C43 stock?
COSMO PHARMACEUTICALS NV (C43.DE) has a market capitalization of 855.95M EUR. This makes C43.DE a Small Cap stock.
C43.DE Technical Analysis
C43.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 9 / 10 to C43.DE. C43.DE gets an excellent profitability rating and is at the same time showing great financial health properties.
C43.DE Financial Highlights
Over the last trailing twelve months C43.DE reported a non-GAAP Earnings per Share(EPS) of 8.16. The EPS increased by 1315.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 49.94% | ||
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| Debt/Equity | 0 |
C43.DE Forecast & Estimates
10 analysts have analysed C43.DE and the average price target is 104.72 EUR. This implies a price increase of 114.58% is expected in the next year compared to the current price of 48.8.
For the next year, analysts expect an EPS growth of -23.67% and a revenue growth -19.4% for C43.DE